Active, not recruitingPhase 2NCT02758717

Nivolumab and Brentuximab Vedotin in Treating Older Patients With Untreated Hodgkin Lymphoma

Studying Classic Hodgkin lymphoma

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Academic and Community Cancer Research United
Principal Investigator: Bruce D Cheson, MD
Academic and Community Cancer Research United
Intervention: Brentuximab Vedotin(drug)
Enrollment: 46 enrolled
Eligibility: All sexes
Timeline: 2016 – 2025

Study locations (9)

Stanford Cancer Institute Palo Alto, Palo Alto, California, United States
MedStar Georgetown University Hospital, Washington D.C., District of Columbia, United States
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
Mayo Clinic, Rochester, Minnesota, United States
Washington University School of Medicine, St Louis, Missouri, United States
Hackensack University Medical Center, Hackensack, New Jersey, United States
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York, New York, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
M D Anderson Cancer Center, Houston, Texas, United States

Collaborators

National Cancer Institute (NCI)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT02758717 on ClinicalTrials.gov

Other trials for Classic Hodgkin lymphoma

Additional recruiting or active studies for the same condition.

See all trials for Classic Hodgkin lymphoma →

← Back to all trials